BACKGROUND Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer…. Continue to publication
About Author
Steve Holmes
- Gold Coast, Australia
- Kiwi-born Waikanae, New Zealand
- CEO at Cholangiocarcinoma Foundation Australia & ( NZ)
- Founder of The Main Beach Foundation – Putting Community Responsibility back into Cancer
Your biggest RISK when responding to a cancer diagnosis is not knowing what you do not know. Your biggest advantage is to begin learning from someone who does. Providing “Targeted Health Literacy”